Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #103

    Lidt om Car-T https://endpts.com/new-car-t-data-look-spectacular-but-how-many-patients-will-take-it-and-when-asco23/

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #104

      longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile https://twitter.com/lymphomahub/status/1666142892270682128

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #105

        Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #106

          Link Preview Image
          Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

          De amerikanske lægemiddelmyndigheder FDA har godkendt det bispecifikke antistof epcoritamab til behandling af patienter med relaps eller refraktært (r/r) storce

          favicon

          (haematologisktidsskrift.dk)

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #107

            God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.

            1 Reply Last reply
            0
            • P Offline
              P Offline
              Pensionisten
              wrote on sidst redigeret af
              #108

              Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt 😉

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #109

                Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #110

                  Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #111

                    so the first article is the new/later cutoff date of January 31, 2023; results very similar

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #112

                      104 efficacy evaluable patients treated with epcoritamab at 48 mg plus R2, the overall response rate (ORR) was 98% (median follow-up, 11.4 months). The complete metabolic response (CMR) was
                      87%

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #113

                        (versus the the immediate prior therapy they progressed on,
                        85% and 58% respectively)

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #114

                          easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide https://dailynews.ascopubs.org/do/positive-responses-seen-follicular-lymphoma-epcoritamab-added-rituximab-and

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #115

                            As far as I remember Genmab was planning to file epco for approval in FL this year. But I don’t remember if it was RR or 1L. Do you?

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #116

                              oh good question, i had assumed RR as that is usually the case for a first approval
                              ...

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #117

                                Godmorgen 🙂

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Stroka
                                  wrote on sidst redigeret af
                                  #118

                                  God morgen 🙂

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #119

                                    Shortpositioner på danske aktier https://www.proinvestor.com/boards/113022

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      Klarussen
                                      wrote on sidst redigeret af
                                      #120

                                      Short Genmab stabil 0,43%, fint, fint. Og det gode ved shorts er jo at de skal købes tilbage på et tidspunkt som Buffet siger 😉

                                      1 Reply Last reply
                                      0
                                      • A Offline
                                        A Offline
                                        AaBforever
                                        wrote on sidst redigeret af
                                        #121

                                        Ja spændende hvornår turen op til 3500 starter...;-)

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Riis7
                                          wrote on sidst redigeret af
                                          #122

                                          Buffet køber ikke aktier unden udbytte og aktietilbagekøbs program:-) Genmabs aktietilbagekøbs program er kun til deres medarbejder:-)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper